In the evolving landscape of diabetes management, novel treatments like semaglutide and retatrutide are gaining traction. These agents, belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist class, offer https://zaynabdxmq301899.azzablog.com/39447510/semaglutide-vs-retatrutide-a-novel-comparison-in-diabetes-management